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doi:10.1Objective: Thoracic aortic aneurysms result from dysregulated remodeling of the vascular extracellular matrix,
which may occur as a result of altered resident cellular function. The present study tested the hypothesis that aortic
fibroblasts undergo a stable change in cellular phenotype during thoracic aortic aneurysm formation.
Methods: Primary murine aortic fibroblasts were isolated from normal and thoracic aortic aneurysm-induced aor-
tas (4 weeks post induction with 0.5 mol/L CaCl2 15 minutes) by the outgrowth method. Normal and thoracic
aortic aneurysm cultures were examined using a focused polymerase chain reaction array to determine fibro-
blast-specific changes in gene expression in the absence and presence of biological stimulation (endothelin-1,
phorbol-12-myristate-13-acetate, angiotensin-II). The relative expression of 38 genes, normalized to 4 house-
keeping genes, was determined, and genes displaying a minimum 2-fold increase/decrease or genes with signif-
icantly different normalized cycle threshold values were considered to have altered expression.
Results: At steady state, thoracic aortic aneurysm fibroblasts revealed elevated expression of several matrix
metalloproteinases (Mmp2, Mmp11, Mmp14), collagen genes/elastin (Col1a1, Col1a2, Col3a1, Eln), and other
matrix proteins, as well as decreased expression ofMmp3, Timp3, and Ltbp1. Moreover, gene expression profiles
in thoracic aortic aneurysm fibroblasts were different than normal fibroblasts after equivalent biological stimuli.
Conclusions: This study demonstrated for the first time that isolated primary aortic fibroblasts from thoracic aor-
tic aneurysm-induced mice possess a unique and stable gene expression profile, and when challenged with bio-
logical stimuli, induce a transcriptional response that is different from normal aortic fibroblasts. Together, these
data suggest that aortic fibroblasts undergo a stable phenotypic change during thoracic aortic aneurysm develop-
ment, which may drive the enhancement of extracellular matrix proteolysis in thoracic aortic aneurysm progres-
sion. (J Thorac Cardiovasc Surg 2010;140:653-9)Thoracic aortic aneurysms (TAAs) develop in response to
pathologic changes that alter the structure and composition
of the aortic extracellular matrix (ECM).1,2 These dynamic
changes produce an imbalance between matrix degradation
and deposition resulting in compromised structural integrity
and a propensity to dilate, dissect, or rupture.2,3 Although
the inciting stimuli remain undefined, it has become clear
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Scellular and molecular mechanisms. Current data from clin-
ical TAA specimens and experimental animal models have
implicated the matrix metalloproteinases (MMPs) as key
mediators of aneurysm formation. Although many studies
have suggested that inflammatory cells are the major source
of MMPs in aneurysm development,4,5 changes in MMP
abundance can also arise as a result of altered production
by the endogenous cellular constituents. For example, LeM-
aire and colleagues5 implicated a role for endogenous cells
in mediating elevated MMP expression in ascending aortic
aneurysm specimens from patients with bicuspid aortic
valves lacking inflammatory infiltrate. Furthermore, work
from this laboratory localized MMP-9 promoter activation
to fibroblasts/fibroblast-derived cells within the developing
murine TAA.6 With many studies reporting a loss of medial
smooth muscle cells (SMCs) during TAA development,7,8 it
is likely that the changes in endogenous cellular constituents
play a significant role in mediating TAA formation and
progression. In a recent report from this laboratory using
a murine model of TAA, aortic dilatation occurred concom-
itantly with a loss of medial SMCs and the emergence of
a subset of fibroblast-derived myofibroblasts.9
Accordingly, thepresent study examined the hypothesis that
aortic fibroblasts undergo a phenotypic transformation thatrdiovascular Surgery c Volume 140, Number 3 653
Abbreviations and Acronyms
Ang ¼ angiotensin
Ct ¼ cycle threshold
ECM ¼ extracellular matrix
ET ¼ endothelin
MMP ¼ matrix metalloproteinase
PCR ¼ polymerase chain reaction
PMA ¼ phorbol-12-myristate-13-acetate
QPCR ¼ quantitative polymerase chain reaction
SMC ¼ smooth muscle cell
TAA ¼ thoracic aortic aneurysm
TGF ¼ transforming growth factor
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pensate for the loss of SMCs in the developing aneurysm. The
hypothesis was tested through 2 primary objectives. The first
objective examined gene expression differences in primary
aortic fibroblasts isolated from either normal mice or mice 4
weeks after TAA induction surgery. The second objective
then determined whether the isolated fibroblasts responded
in similar fashion when equivalently challenged with relevant
biological stimuli. To accomplish these objectives, a custom
quantitative real-time polymerase chain reaction array was
constructed and used to simultaneously determine the relative
expression of multiple determinants of ECM degradation and
deposition in normal and TAA fibroblasts.MATERIALS AND METHODS
Experimental Design
The present study examined gene expression in primary murine aortic fi-
broblasts isolated from normal and TAA-induced mice. Four C57BL/6 J
mice (8–12 weeks old, equal number of male and female mice) underwent
TAA induction surgery with a terminal time-point of 4 weeks post-TAA
induction. At terminal surgery, the descending thoracic aorta was excised
under sterile conditions and processed for fibroblast outgrowth according
to established procedures.10 At the same time, aortas were harvested from
4 unoperated C57BL/6 J age- and gender-matched control mice and
processed identically for fibroblast outgrowth. This animal protocol was
approved by the Medical University of South Carolina Institutional Care
and Use Committee, and all mice were treated and cared for in accordance
with the National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals (Publication No. 85-23, revised 1996).
Operative Procedure
Murine TAAs were induced as previously described.11 Briefly, after an-
esthetic induction, mice were intubated and a surgical plane of anesthesia
wasmaintained using a 2% isoflurane/oxygenmixture. The descending tho-
racic aorta was exposed through a left thoracotomy. A sponge soaked in
0.5 mol/L calcium chloride was then placed in direct contact with the peri-
adventitial surface for 15 minutes. The chest was irrigated and closed in
layers, and the mice were allowed to recover.
Terminal surgical procedures and fibroblast isolation.
Mice were transferred to a laminar flow biosafety cabinet and euthanized
under deep anesthesia by exsanguination induced by right atriotomy. The654 The Journal of Thoracic and Cardiovascular Surganimals were then systemically perfused with sterile saline until the perfus-
ate was clear and the liver was blanched. The descending thoracic aorta was
excised, rinsed in sterile saline, and cut longitudinally. The endothelial cell
layer was removed by gently rubbing the luminal surface with a sterile swab.
The aorta was then cut into approximately ten 13 2 mm pieces and care-
fully placed onto the surface of a dry tissue culture flask (T-75, Cat#13-
680-65; BD Falcon, Fisher Scientific, Pittsburgh, PA). The tissue was al-
lowed to adhere in the absence of medium for 5 to 10 minutes, and then
10 mL of fibroblast growth medium (Fibroblast Growth Medium, Promo-
cell Cat#C39315, Heidelberg, Germany), containing Fibroblast Growth
Supplement (Promocell Cat#C23010; consisting of 1.0 ng/mL basic fibro-
blast growth factor, and 0.5 mg/mL insulin at final concentration) and
20% heat-inactivated fetal-calf serum (Invitrogen, Cat# 10082-147, Carls-
bad, CA), was carefully added to the flask. The flask was placed in a humid-
ified 5% CO2 incubator, and the fibroblasts were allowed to grow out of the
individual tissue chunks. Evidence of fibroblast outgrowth was typically ob-
served within 7 days of plating. Of the 8 cell lines initiated, 4 normal aortic
fibroblast cell lines and 3 TAA cell lines reached confluence within 22 1
days after plating. Fibroblasts were identified as spindle-shaped cells during
log phase growth, and their identity was confirmed by staining log-phase
cells with phalloidin to observe cellular architecture and with cell-type spe-
cific markers to verify purity (DDR2, prolyl-4-hydroxylase, and heavy
chain myosin). The established cell lines were maintained in culture and
split into new flasks when the cell density reached approximately 90% con-
fluence. Fibroblasts in passages 3 to 6 were used for experimental studies.
Cell stimulation. For steady-state analysis, normal and TAA fibro-
blasts were grown to approximately 80% confluence and placed in se-
rum-reduced medium (fibroblast growth medium þ fibroblast growth
supplement) containing 0.1% bovine serum albumin for 24 hours before
harvest. The cells were scraped into cold (4C) phosphate-buffered saline
and collected by centrifugation (3000g). The cell pellet was resuspended
in 300 mL of RNAprotect Cell Reagent (Cat#76526, QIAGEN, Inc, Valen-
cia, CA) and stored at 4C for 24 hours.
For the cellular stimulation studies, normal and TAA fibroblasts were
grown to approximately 70% confluence and then placed in serum-reduced
medium containing 0.1% bovine serum albumin (as detailed above) for
24 hours. The following day, the serum-reduced medium was aspirated
and replaced with 5 mL of the same medium containing 1 nM endothelin
(ET)-1 (Cat# E-7764; Sigma Chemical Co, St Louis, MO), 100 nM angio-
tensin (Ang)-II (Cat# A-9525; Sigma Chemical Co), or 100 nM phorbol-
12-myristate-13-acetate (PMA; Cat# P-8139; Sigma Chemical Co). The
cells were then allowed to grow for an additional 24 hours. At the end of
the stimulation period, the cells were processed as detailed above.
Gene expression analysis. Total RNAwas isolated using the QIA-
GEN RNeasy Plus Mini Kit (Cat#74134, QIAGEN, Inc). RNA quality and
quantity were analyzed with the Experion Automated Electrophoresis Sys-
tem (Bio-Rad Laboratories, Hercules, CA) using an Experion RNA StdSens
Analysis Kit (Cat#700-7103, Bio-Rad Laboratories). One milligram of
high-quality RNA from each cell line was reverse-transcribed to generate
cDNA using an RT2 First Strand Kit (Cat#C-03, SABiosciences, Frederick,
MD), and the cDNAwas immediately assayed for gene expression by quan-
titative PCR (QPCR).
To easily assess the expression of numerous genes from the established
primary cell lines, a custom RT2 Profiler PCR Array (Custom Services; SA-
Biosciences) was designed to test 42 different genes, including 4 house-
keeping control genes, in a 96-well plate format. The generated cDNA
was diluted into RT2 QPCRMaster Mix (Cat#PA-011, containing Hot-Start
Taq polymerase and a SYBR Green/Fluorescein mix specific for Bio-Rad
QPCR systems; SABiosciences), according to the manufacturer’s instruc-
tions, and applied to a 96-well PCRArray plate. QPCRwas performed using
a MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad) with the
following cycling parameters: initial denaturation for 10 minutes at 95C
was followed by 40 cycles of 15 seconds at 95C, 40 seconds at 55C,
and 30 seconds at 72 C. A melt curve was established immediately afterery c September 2010
TABLE 1. List of genes assayed in normal and thoracic aortic aneurysm fibroblasts by quantitative polymerase chain reaction
Target Gene symbol UniGene RefSeq Description
MMPs/TIMPs 1 Mmp2 Mm.29564 NM_008610 Matrix metallopeptidase 2
2 Mmp3 Mm.4993 NM_010809 Matrix metallopeptidase 3
3 Mmp7 Mm.4825 NM_010810 Matrix metallopeptidase 7
4 Mmp8 Mm.16415 NM_008611 Matrix metallopeptidase 8
5 Mmp9 Mm.4406 NM_013599 Matrix metallopeptidase 9
6 Mmp11 Mm.4561 NM_008606 Matrix metallopeptidase 11
7 Mmp12 Mm.2055 NM_008605 Matrix metallopeptidase 12
8 Mmp13 Mm.5022 NM_008607 Matrix metallopeptidase 13
9 Mmp14 Mm.280175 NM_008608 Matrix metallopeptidase 14 (MT1-MMP)
10 Mmp15 Mm.217116 NM_008609 Matrix metallopeptidase 15 (MT2-MMP)
11 Timp1 Mm.8245 NM_011593 Tissue inhibitor of metalloproteinase 1
12 Timp2 Mm.206505 NM_011594 Tissue inhibitor of metalloproteinase 2
13 Timp3 Mm.4871 NM_011595 Tissue inhibitor of metalloproteinase 3
14 Timp4 Mm.255607 NM_080639 Tissue inhibitor of metalloproteinase 4
ECM proteins 15 Col1a1 Mm.277735 NM_007742 Procollagen, type I, alpha 1
16 Col1a2 Mm.277792 NM_007743 Procollagen, type I, alpha 2
17 Col3a1 Mm.249555 NM_009930 Procollagen, type III, alpha 1
18 Col4a1 Mm.738 NM_009931 Procollagen, type IV, alpha 1
19 Col6a1 Mm.2509 NM_009933 Procollagen, type VI, alpha 1
20 Eln Mm.275320 NM_007925 Elastin
21 Ltbp1 Mm.269747 NM_019919 Latent transforming growth factor-beta binding protein 1
22 Ltbp2 Mm.3900 NM_013589 Latent transforming growth factor-beta binding protein 2
23 Fbn1 Mm.271644 NM_007993 Fibrillin 1
24 Lamb1-1 Mm.172674 NM_008482 Laminin B1 subunit 1
25 Lamb2 Mm.425599 NM_008483 Laminin, beta-2
26 Lamb3 Mm.435441 NM_008484 Laminin, beta-3
27 Fn1 Mm.193099 NM_010233 Fibronectin 1
28 Spp1 Mm.288474 NM_009263 Secreted phosphoprotein 1 (osteopontin)
29 Thbs1 Mm.4159 NM_011580 Thrombospondin 1
30 Sparc Mm.291442 NM_009242 Secreted acidic cysteine rich glycoprotein (SPARC)
31 Ager Mm.3383 NM_007425 Advanced glycosylation end-product receptor (RAGE)
Transcription factors 32 Sp1 Mm.4618 NM_013672 Transacting transcription factor 1 (Sp1)
33 Sp3 Mm.124328 NM_011450 Transacting transcription factor 3 (Sp3)
34 Jun Mm.275071 NM_010591 Jun oncogene (Jun)
35 Junb Mm.1167 NM_008416 Jun-B oncogene (Jun b)
36 Fos Mm.246513 NM_010234 FBJ osteosarcoma oncogene (Fos)
37 Fosb Mm.248335 NM_008036 FBJ osteosarcoma oncogene B (Fos b)
38 Etv4 Mm.5025 NM_008815 Ets variant gene 4 (E1A enhancer binding protein) (PEA-3)
House-keeping genes 39 Gusb Mm.3317 NM_010368 Glucuronidase, beta
40 Hprt1 Mm.299381 NM_013556 Hypoxanthine guanine phosphoribosyl transferase 1
41 Hspb1 Mm.13849 NM_013560 Heat shock protein 1 (Hsp27)
42 Gapdh Mm.343110 NM_008084 Glyceraldehyde-3-phosphate dehydrogenase
MMP/TIMP, Matrix metalloproteinase/tissue inhibitor of metalloproteinase; ECM, extracellular matrix. Data compiled using Rebhan and colleagues’ study.27
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QPCR product for each gene-specific primer set (1 minute at 95 C, 2 min-
utes at 65 C, followed by 60 cycles of 15 seconds at 65 Cwith an increase
of 0.5 C per cycle). Negative controls were run on each plate to verify the
absence of genomic DNA contamination (no reverse transcription control)
and the absence of overall DNA contamination in the PCR system and
working environment (no template control).
Data analysis. Cycle threshold (Ct) values were recorded and fold
change in steady-state gene expression between TAA fibroblasts and nor-
mal fibroblasts was calculated using the DDCt method (see Table 1 for
a complete listing of genes examined, including housekeeping genes).
Fold expression values greater than 2.0 or less than 0.5 were consideredThe Journal of Thoracic and Cato have a significant change in gene expression. In addition, any gene that
displayed a significant difference in mean DCt value (TAA vs normal by
2-sided, 2-tailed t test; P<.05) was likewise considered to have a significant
change in expression. Ct values of 35.0 or greater were considered non-cy-
cling and were removed from analysis. Of the genes tested, primers for
Mmp8, Mmp12, Mmp7, and Timp4 consistently produced multiple peaks
on melt-curve analysis indicating that more than 1 product was being ampli-
fied in those wells. Accordingly, these genes were also removed from anal-
ysis. In addition, Mmp9, Timp1, and Lamb3 did not consistently cycle
because of low target concentration or poor primer design. To measure
Mmp9 and Timp1 gene expression, TaqMan primer/probe sets were used
with same QPCR conditions indicated above (Mmp9, Cat#rdiovascular Surgery c Volume 140, Number 3 655
TABLE 2. Relative fold gene expression in thoracic aortic aneurysm fibroblasts compared with normal fibroblasts at steady-state and after
stimulation with various growth factors at the indicated concentrations
Fold expression
(TAA fibroblasts vs normal fibroblasts)
Gene symbol Steady-state ET-1 (1 nM) PMA (100 nM) AngII (100 nM)
MMPs/TIMPs Mmp2 6.54 (P¼ .0055) 4.46 (P¼ .0239) 3.65 (P¼ .0472) 5.94 (P¼ .0171)
Mmp3 0.41 (P¼ .3622) 0.26 (P¼ .2470) 0.06 (P¼ .0137) 0.22 (P¼ .2382)
Mmp9 0.09 (P¼ .0488) 0.04 (P¼ .0012) 0.21 (P¼ .1109) 0.09 (P¼ .1828)
Mmp11 9.78 (P¼ .0027) 2.78 (P¼ .2959) 2.03 (P¼ .1184) 7.26 (P¼ .0278)
Mmp13 1.11 (P¼ .8461) 0.97 (P¼ .9514) 0.11 (P¼ .0280) 0.42 (P¼ .7376)
Mmp14 2.01 (P¼ .1014) 2.13 (P¼ .0008) 1.78 (P¼ .1450) 1.87 (P¼ .1579)
Mmp15 1.17 (P¼ .8590) 0.66 (P¼ .3911) Dec 0.23 (P¼ .0902)
Timp1 1.41 (P¼ .2415) 0.99 (P¼ .9766) 1.53 (P¼ .1271) 1.39 (P¼ .4637)
Timp2 1.11 (P¼ .5787) 0.95 (P¼ .8977) 0.95 (P¼ .8377) 1.27 (P¼ .3828)
Timp3 0.33 (P¼ .1490) 0.49 (P¼ .3012) 0.43 (P¼ .0799) 0.30 (P¼ .0896)
Collagen/elastic architecture Col1a1 2.52 (P¼ .0583) 1.83 (P¼ .0793) 2.99 (P¼ .0015) 1.84 (P¼ .2291)
Col1a2 3.45 (P¼ .0082) 2.90 (P¼ .0007) 3.61 (P¼ .0047) 3.46 (P¼ .0049)
Col3a1 4.83 (P¼ .0083) 3.51 (P¼ .0102) 4.52 (P¼ .0120) 4.05 (P¼ .0109)
Col4a1 2.82 (P¼ .0039) 2.36 (P¼ .0284) 2.22 (P¼ .3715) 1.94 (P¼ .4345)
Col6a1 1.67 (P¼ .2485) 1.47 (P¼ .4708) 1.52 (P¼ .5061) 1.41 (P¼ .4827)
Eln 2.30 (P¼ .2558) 2.32 (P¼ .2918) 0.79 (P¼ .7256) 2.24 (P¼ .4751)
Ltbp-1 0.09 (P¼ .0564) 0.21 (P¼ .0323) 0.04 (P¼ .0033) 0.19 (P¼ .0955)
Ltbp-2 1.71 (P¼ .2016) 1.39 (P¼ .4174) 1.44 (P¼ .3357) 1.63 (P¼ .3735)
Fbn1 1.83 (P¼ .2042) 2.13 (P¼ .1269) 2.33 (P¼ .1862) 2.55 (P¼ .1643)
Other ECM Lamb1-1 1.66 (P¼ .1437) 1.61 (P¼ .3753) 0.99 (P¼ .9830) 2.02 (P¼ .1812)
Lamb2 21.96 (P¼ .0378) 1.36 (P¼ .7058) 0.05 (P¼ .0194) 0.56 (P¼ .3979)
Fn1 2.23 (P¼ .1582) 1.96 (P¼ .1730) 1.56 (P¼ .3862) 1.83 (P¼ .4078)
Spp1 2.43 (P¼ .2790) 3.15 (P¼ .3129) 0.17 (P¼ .6975) 1.15 (P¼ .9537)
Thbs1 0.88 (P¼ .5526) 0.59 (P¼ .0240) 1.39 (P¼ .2732) 0.70 (P¼ .3291)
Sparc 2.10 (P¼ .1208) 2.25 (P¼ .0624) 1.40 (P¼ .5110) 0.90 (P¼ .8262)
Ager 0.72 (P¼ .4922) 0.69 (P¼ .5648) 0.73 (P¼ .5835) 0.90 (P¼ .8769)
Transcription factors Sp1 1.68 (P¼ .1245) 1.21 (P¼ .5112) 1.22 (P¼ .5883) 0.97 (P¼ .8670)
Sp3 0.98 (P¼ .9197) 1.13 (P¼ .7552) 1.03 (P¼ .9300) 0.94 (P¼ .8385)
Jun 1.49 (P¼ .6169) 3.71 (P¼ .0106) 2.63 (P¼ .0460) 2.28 (P¼ .0174)
Junb 0.82 (P¼ .7838) 1.28 (P¼ .7831) 1.46 (P¼ .4151) ND
Fos 2.14 (P¼ .7734) 1.71 (P¼ .4049) 0.46 (P¼ .4656) 0.97 (P¼ .9632)
Fosb 2.41 (P¼ .3959) 3.40 (P¼ .2602) 5.21 (P¼ .1182) 1.67 (P¼ .6711)
Etv4 0.91 (P¼ .7819) 1.14 (P¼ .7663) 0.44 (P¼ .2232) 0.82 (P¼ .6757)
MMP/TIMP, Matrix metalloproteinase/tissue inhibitor of metalloproteinase; TAA, thoracic aortic aneurysm; ECM, extracellular matrix; ET, endothelin; PMA, phorbol-12-myris-
tate-13-acetate; AngII, angiotensin-II; Dec, decreased below detection with stimulation; ND, not detectable with stimulation.
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Foster City, CA). There were 2 incidents of stimulus-induced increase in
Ct values (PMA, Mmp15; and AngII, Junb). In PMA-treated cells, each
stimulated control cell line yielded a measurable Ct value for Mmp15,
whereas each stimulated TAA cell line produced Ct values of greater than
35.0. In AngII-treated cells, Junb expression was suppressed in both normal
and TAA fibroblasts after stimulation.
Gene expression in each stimulated cell line was determined in a similar
manner. To more easily represent the expression differences between nor-
mal and TAA fibroblasts, genes were clustered into similar gene families,
and total gene expression was depicted as an area profile on a radar plot.
Each axis displays the sum of the relative fold change in gene expression
for a given gene cluster in the TAA fibroblasts compared with the control
fibroblasts. The genes included in each cluster were 1) MMP/TIMP genes
(Mmp2, Mmp3, Mmp9, Mmp11, Mmp13, Mmp14, Mmp15, Timp1, Timp2,
Timp3); 2) collagen/elastic architecture genes (Col1a1, Col1a2, Col3a1,
Col4a1, Col6a1, Eln, Ltbp1, Ltbp2, Fbn1); and 3) other ECM genes
(Lamb1-1, Lamb2, Lamb3, Fn1, Spp1, Thbs1, Sparc, Ager).656 The Journal of Thoracic and Cardiovascular SurgRESULTS
Relative Gene Expression Analysis at Steady-State
Primary aortic fibroblasts from normal and TAA-induced
mice were analyzed to determine the relative expression of
38 genes and 4 housekeeping genes (Table 1) under
steady-state culture conditions using a single custom
QPCR array plate per cell line. The TAA mice displayed
a relative increase in Mmp2, Mmp11, and Mmp14 expres-
sion, and a relative decrease ofMmp3, Mmp9, and Timp3 ex-
pression (Table 2, Steady-State). Furthermore, the steady-
state expression of several collagen genes and elastin was
also elevated (Col1a1, Col1a2, Col1a3, Col4a1, and Eln),
whereas the expression of Ltbp-1 was decreased (Table 2).
In addition, several other ECM proteins displayed elevated
expression (Lamb2, Fn1, Spp1, and Sparc) (Table 2). Last,ery c September 2010
FIGURE 1. Analysis of gene expression after cellular stimulation. Relative gene expression in normal and TAA fibroblast cell lines was analyzed in the
absence (steady-state) or presence of biological stimuli. Cells were treated with 1 nM ET-1, 100 nM AngII, or 100 nM PMA for 24 hours and then analyzed
by QPCR. Relative fold expression results were clustered in functional groups (MMP/TIMP, collagen/elastin, other ECM), and total gene expression was
depicted as an area profile on a radar plot. Each axis displays the sum of the relative fold change in gene expression for a given gene cluster in the TAA
fibroblasts compared with the control fibroblasts.MMP/TIMP,Matrix metalloproteinase/tissue inhibitor of metalloproteinase; TAA, thoracic aortic aneurysm;
ECM, extracellular matrix; ET, endothelin; PMA, phorbol-12-myristate-13-acetate; AngII, angiotensin-II.
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to be involved in regulating matrix turnover was assessed.
The TAA fibroblasts demonstrated increased steady-state
expression of Fos and Fosb (Table 2).
Relative Gene Expression Analysis After Stimulation
With Endothelin-1, Phorbol-12-Myristate-13-
Acetate, and Angiotensin-II
To determine whether normal and TAA fibroblasts re-
spond in similar fashion to equivalent biological stimuli
(ET-1, PMA, AngII), both sets of fibroblasts were stimulated
for 24 hours, and the relative changes in gene expression
were examined. In almost all cases, the TAA fibroblasts re-
sponded more robustly than the normal fibroblasts to biolog-
ical stimulus (Table 2, ET-1, PMA, AngII). To more easily
demonstrate the relative changes in gene expression, the re-
sults in Table 2 were further analyzed by cluster analysis in
the following functional groups: MMP/TIMP, collagen/elas-
tic architecture, and other ECM. Figure 1 reveals the relative
fold expression results for normal and TAA fibroblasts
showing that the gene expression profiles for the TAA fibro-
blasts were different from normal fibroblasts at steady-state
and after exposure to equivalent biological stimuli.
DISCUSSION
Previous clinical and experimental aneurysm studies have
demonstrated significant changes in aortic structure and com-
position in the developing TAA. These changes include dis-
ruption of the medial elastic lamellae,12,13 alterations inThe Journal of Thoracic and Cacollagen deposition,12–14 changes in cellular content charac-
terized by the loss of SMCs,7,8 and alterations in aortic tran-
scriptional profiles.6,15,16 In addition, previous studies from
this laboratory have identified fibroblasts/fibroblast-derived
cells as a potential source for enhanced MMP transcriptional
activity during TAAdevelopment inmice.6,9 Taken together,
this led us to hypothesize that aortic fibroblasts are an impor-
tant cellular componentwithin the aorticwall, which undergo
a stable phenotypic change during TAA development, allow-
ing them to adapt to the rapidly degrading conditions andme-
diate the vascular remodeling process. To test this
hypothesis, primary thoracic aortic fibroblasts were isolated
fromnormal andTAA-inducedmice, and transcriptional pro-
files of key determinants of matrix degradation and deposi-
tion were assessed in the absence and presence of relevant
biological stimuli. The unique outcomes of this study are
3-fold. First, the present study demonstrated significant tran-
scriptional changes in TAA fibroblasts compared with nor-
mal aortic fibroblasts. These results are consistent with
expectations of enhanced degradation and remodeling of
the vascular ECM during TAA development that may ensue,
in part, because of altered fibroblast function. Second, when
isolated fibroblasts were challenged by treatment with rele-
vant biological stimuli (ET-1, AngII, PMA), differential tran-
scriptional responses were observed between normal and
TAA fibroblasts, suggesting that intracellular signaling path-
ways in the TAA fibroblasts may be altered, and thus may re-
spond differently to equivalent stimuli. Last, the observed
gene expression differences between normal and TAArdiovascular Surgery c Volume 140, Number 3 657
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cell passages required to establish the in vitro cultures. By us-
ing an established fibroblast outgrowth procedure,10 multiple
primary cell lines from both normal and TAA-induced ani-
mals were established in vitro. The highly reproducible tran-
scriptional differences between the TAA and the normal
fibroblasts are therefore not a by-product of selection during
in vitro establishment or a direct result of cell passaging, but
due to a stable alteration in transcriptional activity induced
during the process of aneurysm development in vivo. Taken
together, the results of this study support the hypothesis that
aortic fibroblasts undergo a stable phenotypic transformation
during TAA development, and that these changes in gene ex-
pression may alter normal fibroblast function and contribute
to TAA formation and progression.
Steady-State Changes Gene Expression
To assess transcriptional differences between normal and
TAA fibroblasts, QPCR was performed using a custom-de-
signed PCRarray to assess the gene expression of several crit-
ical determinants of matrix degradation and deposition,
known to be involved in TAA development. Previous studies
from this laboratory have examined aortic tissue from normal
and TAA mice, and have demonstrated TAA-dependent
changes in gene transcription and protein abundance of
MMPs and transforming growth factor (TGF)-b pathway
components.6,15 Accordingly, it was hypothesized that if
the aortic fibroblast plays a dominant role in TAA develop-
ment, isolated aortic fibroblasts from TAA tissue would like-
wise display an altered transcriptional profile compared with
normal aortic fibroblasts. Indeed, our results were consistent
with that hypothesis. The TAAfibroblasts displayed a distinct
pattern of gene expression reflecting enhanced expression of
severalMMPs (Mmp2,Mmp11, andMmp14),matrix proteins
(Col1a1, Col1a2, Col3a1, Col4a1, Eln, Lamb2, Fn1, Spp1,
and Sparc), and transcription factors (Fos and Fosb), along
with the decreased expression of Mmp3, Mmp9, Timp3, and
Ltbp1. The observed elevated expression of MMP genes
was highly consistent with previous studies from this labora-
tory demonstrating a direct role for increased MMP produc-
tion during TAA development in this model.6,17 Thus, the
stable elevation of MMP transcription in TAA fibroblasts ar-
gues that this differentiated cell-type plays a critical role in de-
grading the ECM during TAA formation and progression.
Although many studies analyzing clinical TAA speci-
mens have demonstrated elevated collagenase activity
(MMP-dependent),1,5,18,19 few have examined aortic colla-
gen content or expression directly.14,20 The present study
demonstrates a robust elevation of collagen gene expression
in the TAA fibroblasts. Although counterintuitive to the
enhanced ECM degradation that takes place during TAA
development, others have described elevated collagen
expression and regional deposition in TAA tissue. For exam-
ple, Iliopoulos and coworkers13 have suggested that colla-658 The Journal of Thoracic and Cardiovascular Surggen content, although diminished in the aortic media, is
elevated in the adventitial region of the aorta, resulting in
no net gain or loss of total collagen content. Similarly, Della
Corte and colleagues12 have demonstrated regional differ-
ences in collagen content in the greater versus lesser curva-
ture of the ascending aorta from aneurysmal patients with
bicuspid aortic valves. Collectively, these studies suggest
that the enhancement of collagen expression may coincide
with TAA development and may result in the regional depo-
sition of newly formed collagen fibers. In a recent report
from this laboratory, medial and adventitial collagen content
were measured over the 16-week time-course of TAA devel-
opment in this model.9 No net change was observed in either
the medial or adventitial compartment. Although this may
suggest a lack of collagen degradation, given the present
results demonstrating elevated MMP and collagen gene ex-
pression in the isolated TAA fibroblasts, it is more likely that
collagen degradation and deposition are balanced in regard
to the total content. This is further supported by the observa-
tion that Sparc (secreted protein acidic and rich in cysteine)
expression is elevated in the TAA fibroblasts, suggesting
that these cells possess a synthetic phenotype, primed to de-
posit newly processed collagen fibers. The organizational
structure of the collagen matrix, on the other hand, may be
significantly remodeled during TAA development, as has
been demonstrated in the postinfarct myocardium.21 Of in-
terest, the present study also identified decreased expression
of Ltbp-1 (latent TGF-b binding protein-1), an ECM struc-
tural protein that serves to bind and sequester the small latent
complex of TGF-b. TGF-b is best known for its ability to in-
duce collagen gene expression but may also play a role in ex-
acerbating vascular remodeling during TAA development.22
Accordingly, it follows that a decrease in Ltbp-1 expression
may lead to an increase in the extracellular levels of TGF-b
and enhancement of collagen gene expression. Moreover,
elevated TGF-b signaling has also been associated with
the induction of MMP expression and abundance.23,24
To further demonstrate the stability of the observed pheno-
typic change between isolated normal and TAA fibroblasts,
the expression levels of several transcription factors impli-
cated in regulating MMP-dependent transcription were as-
sessed. Notably, Fos and Fosb, family members and
components of the AP-1 transcription factor, were both sta-
bly induced andmay play a direct role in the observed change
in transcriptional profile of the TAA fibroblasts.
Stimulated Changes in Gene Expression
In an effort to further define the phenotypic change of the
TAA fibroblasts, gene expression profiles were also
determined after treatment with relevant biological stimuli
(ET-1,25 AngII,26 PMA). When comparing relative gene ex-
pression between treated normal and TAA fibroblasts within
gene family clusters, clear differences in overall transcrip-
tional profiles were observed after treatment with each agent.ery c September 2010
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SAlthough it was anticipated that the MMP genes in the TAA
fibroblasts would be robustly induced in response to some
stimuli (eg, ET-1, PMA), the blunted response observed
may be a direct result of altered downstream signaling path-
ways. Given that these genes were already highly expressed
in the TAA fibroblast, this may further suggest that the intra-
cellular signaling pathways have become uncoupled from
receptor activation in these cells. These results further sub-
stantiate the hypothesis that the TAA fibroblasts have under-
gone a stable phenotypic change and may suggest that the
alterations in transcriptional response are a direct result of
reconfigured intracellular signaling pathways in the TAA
fibroblasts.
Limitations
Because the present study examines gene expression pro-
files in cultured primary aortic cell lines, several limitations
must be noted. First, care must be taken in extrapolating
changes in gene expression with altered protein levels.
Although increased or decreased gene expression often equa-
tes to coordinate changes protein translation, transcriptional
and translational regulation must be considered. Second,
although this murine model of TAA has been well described
and recapitulates many of the hallmarks of human aneurys-
mal disease, some aspects such as atherosclerosis and intra-
luminal thrombosis, are not replicated at the time-points
studied. Accordingly, care should be taken in the extrapola-
tion of these results to human TAAs. Last, although a signif-
icant effect of gender on aortic dilatation has not previously
been demonstrated in this model system, gender-dependent
differences in aortic gene expression cannot be ruled out. Ad-
ditional studies will be required to ascertain whether a signif-
icant interaction between gender and gene expression exist.
CONCLUSIONS
Despite limitations, the present study demonstrated for the
first time that isolated primary aortic fibroblasts from TAA
mice possess a stable and unique phenotype defined by al-
tered gene expression profiles at steady-state and in response
to biological stimuli. This distinctive cellular population
may emerge as the major cellular mediator of vascular re-
modeling during TAA development and may drive the en-
hancement of ECM proteolysis in TAA progression.
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